| 摘要 |
The compounds of the present invention are prodrugs of modulators of the Cannabinoid-1 (CB 1 ) receptor and are useful in the treatment, prevention a nd suppression of diseases mediated by the Cannabinoid- 1 (CB 1) receptor. I n particular, compounds of the present invention are 5 prodrugs of antagonis ts or inverse agonists of the CB1 receptor. The invention is concerned with the use of these compounds to be converted to compounds that modulate the Ca nnabinoid-1 (CB 1 ) receptor. As such, the compounds of the present inventio n are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, n euro-inflammatory disorders including multiple sclerosis and Guillain- 10 Ba rre syndrome and the inflammatory sequelae of viral encephalitis, cerebral v ascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Par kinson's disease, movement disorders, and schizophrenia.
|
